Page 2 - Small Molecule News Today

Nuvation Bio Inc. said on March 25 it will acquire Anheart Therapeutics Ltd., a U.S.- and China-based precision oncology company, in an all-stock transaction, adding Anheart’s ROS1-inhibiting lung cancer drug, taletrectinib (AB-106), to its pipeline.

/PRNewswire/ -- The "Global Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug...

Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The "Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead Generation, Optimization),...

Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Companies covered in this study are Medline Industries, Inc., Teleflex Incorporated, Boston Scientific Corporation, BD (Becton, Dickinson and Company),...

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The